OVERVIEW

X-Linked Hypophosphatemia: Improving Clinician Awareness and Management is organized by Rockpointe Corporation.

Release date: September 5, 2019
Expiration date: September 5, 2020

Accreditation:
CME Credit Designation?
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Abim Moc Designation
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Overview:
Treatment for patients with X-linked hypophosphatemia (XLH) has long been hindered by conventional agents’ monitoring requirements, adverse events, and limited efficacy. Fortunately, in April 2018, an FGF23 blocking antibody became the first FDA-approved agent for XLH. However, because XLH remains a rare disease, clinicians may not be properly equipped to recognize and manage it.

This CME activity, “X-Linked Hypophosphatemia: Improving Clinician Awareness and Management,” will help participants recognize the clinical presentation of XLH, identify the potential short- and long-term complications of XLH, and understand the latest evidence on and role of the recently approved breakthroughs.

Educational Objectives:
This program is designed to address the following National Academy of Medicine (NAM) competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
• Recognize the clinical presentation of XLH
• Identify the potential short- and long-term complications of XLH
• Discuss the efficacy and safety data for newly approved agents for XLH
• Incorporate clinical data and expert recommendations, which include newly approved therapies in management plans for adolescents and adults with XLH